Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2013, Vol. 18 ›› Issue (12): 1430-1435.
Previous Articles Next Articles
WAN Jing-zhi, YUAN Ding, WANG Ting
Received:
2013-05-12
Revised:
2013-11-16
Online:
2013-12-26
Published:
2014-01-04
CLC Number:
WAN Jing-zhi, YUAN Ding, WANG Ting. Research advances in Sirt1 regulating microRNA[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1430-1435.
Add to citation manager EndNote|Ris|BibTeX
URL: https://manu41.magtech.com.cn/Jweb_clyl/EN/
https://manu41.magtech.com.cn/Jweb_clyl/EN/Y2013/V18/I12/1430
[1] Michishita E, Park JY, Burneskis JM, et al. Evolutionarily conserved and nonconserved cellular localizations and functions of human Sirt proteins[J]. Mol Biol Cell, 2005, 16(10): 4623- 4635. [2] Moynihan KA, Grimm AA, Plueger MM, et al. Increased dos-age of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice[J]. Cell Metab , 2005, 2(2): 105- 117. [3] Tanno M, Sakamoto J, Miura T, et al. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase Sirt1[J]. J Biol Chem, 2007, 282(9): 6823- 6832. [4] Vaquero A, Scher M, Lee D, et al. Human Sirt1 interacts with histone H1 and promotes formation of facultative heterochromatin[J]. Mol Cell, 2004, 16(1): 93- 105. [5] Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase Sirt1 in cancer[J]. Cancer Res ,2009, 69(5): 1702- 1705. [6] Wang C, Chen L, Hou X, et al. Interactions between E2F1 and Sirt1 regulate apoptotic response to DNA damage[J]. Nat Cell Biol, 2006, 8(9): 1025- 1031. [7] Heltweg B, Gatbonton T, Schuler AD, et al. Antitumor activity of a small-mole-cule inhibitor of human silent information regulator 2 enzymes[J]. Cancer Res, 2006, 66(8): 4368- 4377. [8] Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress[J].Cell, 2001, 107(2): 137- 148. [9] Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function[J]. Biol Chem J , 2007, 404(1): 1- 13. [10] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism,and function[J]. Cell, 2004, 116(2): 281- 297. [11] Luan S, Sun L, Huang F. MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251[J]. Arch Med Res, 2010, 41(2): 67- 74. [12] Pogribny IP, Muskhelishvili L, Tryndyak VP, et al. The tumor-promoting activity of 2-acetylamino?uorene is associated with disruption of the p53 signaling pathway and the balance between apoptosis and cell proliferation[J]. Toxicol Appl Pharmacol, 2009, 235(3): 305- 311. [13] Keitaro K, Yasunori F, Yoshinori N, et al. miRNA-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms[J]. Prostate, 2010, 70(14): 1501- 1512. [14] Castro RE,Ferreira DM,Afonso MB, et al. miRNA-34a/Sirt1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease[J]. J Hepatol, 2013, 58(1): 119- 125. [15] Ting Z, Jian L, Alex FC. MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1[J]. Am J Physiol Endocrinol Metab, 2010, 299(1): E110- E116. [16] Rossella M, Viviana C, Marina C, et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1[J]. Circulation, 2009,120(15): 1524- 1532. [17] Huquan Y, Ming H, Ray Z, et al. MicroRNA-217 Promotes Ethanol-induced Fat Accumulation in Hepatocytes by Down-regulating Sirt1[J]. J Biol Chem, 2012,287(13): 9817- 9826. [18] Zhang HS, Wu TC, Sang WW, et al. miRNA-217 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation by down-regulation of Sirt1[J]. Biochimi Biophys Acta, 2012, 1823(5): 1017- 1023. [19] Nicole S, David TH, Thomas P, et al. Target gene repression mediated by miRNAs miRNA-181c and miRNA-9 both of which are down-regulated by amyloid-β[J]. J Mol Neurosci, 2012, 46(2): 324- 335. [20] Kathryn MR, Kathryn FM, Akiko S, et al. Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice[J]. Aging Cell, 2008, 7(1): 71- 88. [21] Laura RS, Amar DS, Jaime T, et al. miRNAs regulate Sirt1 expression during mouse embruonic stem cell differentiation and in adult mouse tissues[J]. Aging (Albany NY), 2010, 2(7): 415- 431. [22] Gabriel E, Yuan Y, Muhua Y, et al. miRNA-200a Regulates Sirt1 Expression and Epithelial to Mesenchymal Transition (EMT)-like Transformation in Mammary Epithelial Cells[J]. J Biol Chem, 2011, 286(29): 25992- 26002. [23] Rane S, He M, Sayed D. Downregulation of miRNA-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes[J]. Circ Res 2009, 104(7): 879- 886. [24] Xu WH, Yao XY, Yu HJ, et al. Downregulation of miRNA-199a may play a role in3-nitropropionic acid induced ischemic tolerance in rat brain[J]. Brain Res, 2012, 1429: 116- 123. [25] Tony BK, Ewa FK, Anders J, et al. miRNA-449 inhibits cell proliferation and is down-regulated in gastric cancer[ J]. Molecular Cancer, 2011, 10(29): 1- 12. [26] Zhu H, Yang Y, Wang Y, et al. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1[J]. Cardiovasc Res, 2011, 92(1): 75- 84. [27] Liu P, Wilson MJ. miRNA-520c and miRNA-373 Upregulate MMP9 Expression by Targeting mTOR and Sirt1, and Activate the Ras/Raf/MEK/Erk Signaling Pathway and NF- kB Factor in Human Fibrosarcoma Cells[J]. J Cell Physiol , 2012, 227(2): 867- 876. [28] Dan X, Fumitaka T, Yumiko H, et al. miRNA-22 represses cancer progression by inducing cellular senescence[J]. J Cell Bio, 2011, 193(2): 409- 424. [29] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to the rapeutics[J]. Science, 2002, 297(5580): 353- 356. [30] Kim YJ, Hwang SH, Lee SY, et al. miRNA-486-5p induces replicative senescence of human adipose tissue-derived mesenchymal stem cells and its expression is controlled by high glucose[J]. Stem Cells Dev, 2012, 21(10): 1749- 1760. [31] Jun G, Wenyuan W, Yingwei M, et al. A novel pathway regulates memory and plasticity via Sirt1 and miRNA-134[J].Nature, 2010, 466(26): 1105- 1109. [32] Strum JC, Johnson JH, Ward J, et al. MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1[J]. Mol Endocrinol, 2009, 23(11): 1876- 1884. [33] Na L, Senthilkumar M, Ruqiang L, et al. Increased expression of miRNA-34a and miRNA-93 in rat liver during aging, and their impact on the expression of Mgst1 and Sirt1[J]. Mech Ageing and Dev , 2011, 132(3): 75- 85. [34] Rakefet P, Naomi EZ, Biana S, et al. MicroRNAs in the growth plate are responsive to nutritional cues: association between miRNA-140 and Sirt1[J]. J Nutr Biochem, 2012, 23(11): 1474- 1481. [35] Pia Rivetti di Val Cervo, Lena AM, Nicoloso M, et al. p63-microRNA feedback in keratinocyte senescence[J]. Proc Natl Acad Sci U S A, 2012, 109(4): 1133- 1138. [36] Yeon JK, Soo HH, Sun YL, et al. miRNA-486-5p Induces Replicative Senescence of Human Adipose Tissue-Derived Mesenchymal Stem Cells and Its Expression Is Controlled by High Glucose[J]. Stem Cells Dev, 2012, 21(10): 1749- 1760. [37] Xinyu C, Hongsheng Z, Tongchao W, et al. Down-regulation of NAMPT expression by miRNA-182 is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation[J]. Int J Biochem Cell Biol, 2013, 45(2): 292- 298. [38] Shweta R, Minzhen H, Danish S, et al. An antagonism between the AKT and beta-adrenergic signaling pathways mediated through their reciprocal effects on miRNA-199a-5p[J]. Cell Signal, 2010, 22(7): 1054- 1062. |
[1] | MA A'xue, LU Xiaohong, DONG Bo, WANG Dong. Research progress of exosomal miRNA in skin wound healing and regeneration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 919-924. |
[2] | WU Shuai, YANG Jun, ZHENG Yun. Dual role of miRNA in breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 814-821. |
[3] | DING Hao, GAO Zhenhua, ZHENG Yun. Research progress of microRNA in diagnosis and treatment of prostate cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 696-708. |
[4] | ZHOU Guangchen, LIU Yixi, ZHENG Yun. Colorectal cancer and microRNA: research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 575-587. |
[5] | ZHANG Jianmin, LENG Yufang, LIU Xin, REN Yixing, SHI Yajing, CHEN Feng. Research progress on the mechanism of miRNA in intestinal ischemia-reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 332-340. |
[6] | LU Chenyu, YANG Jun, LIU Yixi, ZHENG Yun. Function and regulation of miRNAs associated with Parkinson's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 775-783. |
[7] | ZHOU Hongping, YANG Xingxin, ZHUANG Rangxiao, SHAO Yidan, XI Jianjun, LIAO Li, REN Bailu, WANG Pingping, YU Shuying, SHI Tingting. Effects of activated carbon N-acetylcysteine sustained-release microcapsule on miRNA of non-alcoholic fatty liver disease in young rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 263-270. |
[8] | PAN Xiaoqiu, ZHAI Hongjun, LI Lihui, BAN Yaolin. Study on differential expression of the mi-RNA in the deep second degree burns [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1321-1328. |
[9] | XIE Zhen, KANG Hua, HE Licheng, KUANG Rong. Effects and mechanism of deep-sea fish oil on blood lipid in hyperlipidemia rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 870-874. |
[10] | MEI Ying, LIU Chaoqi. Advances in research of miRNA regulated tumor-associated gene c-met [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 204-209. |
[11] | KONG Xiang, HUA Qiang, MENG Xiangjian, YAO Xinming, WANG Yong, XIA Libin. Clinical implications of circulating miRNA-101 expression level in patients with newly diagnosed type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1406-1409. |
[12] | SONG Li-ying, PENG Xiang-dong, WANG Chun-jiang, GUO Ren, LIU Shi-kun. Recent progress in the role of miRNA in hepatic stellate cells activation and the chronic hepatic diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1422-1428. |
[13] | GUO Yu, ZHOU Hong-hao, LIU Zhao-qian. MiRNA and interindividual difference in drug response [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 443-448. |
[14] | WANG Ping, YIN Tao, ZHOU Bo-ting. Regulation on miRNA to osteoporosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 110-114. |
[15] | GONG Zhi-cheng, HUANG Qiong, LIU Zhao-qian. Research progress of miRNA in diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(2): 214-218. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||